Allogene Therapeutics Inc
NASDAQ:ALLO

Watchlist Manager
Allogene Therapeutics Inc Logo
Allogene Therapeutics Inc
NASDAQ:ALLO
Watchlist
Price: 2.54 USD -6.62% Market Closed
Market Cap: 531.1m USD
Have any thoughts about
Allogene Therapeutics Inc?
Write Note

P/FCFE
Price to FCFE

-2.4
Current
-3.5
Median
27.3
Industry
Higher than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-2.4
=
Market Cap
532.1m USD
/
FCFE
-217.9m USD
All Countries
Close
 
US
Allogene Therapeutics Inc
NASDAQ:ALLO
Average P/FCFE: 31.6
Negative Multiple: -2.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 183 345.6
US
Abbvie Inc
NYSE:ABBV
12
US
Amgen Inc
NASDAQ:AMGN
26.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -90.6
US
Gilead Sciences Inc
NASDAQ:GILD
11.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -431
AU
CSL Ltd
ASX:CSL
80.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.3
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.8

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More